Georgia Bio Receives Increase in State Funds for Teacher Training Initiative and Reveals Most Recent Impact Numbers

The program has reached 81,413 students and 519 teachers across Georgia.

Atlanta, GA (August 5, 2024) – Georgia Bio’s Biotech Teacher Training Initiative (BTTI), formerly known as the Rural Teacher Training Initiative (RTTI), secured a significant increase in state funding in Georgia’s Fiscal Year 2025 budget. Total state funding now sits at $500,000. This investment from the state will be matched by industry donations in both cash and equipment, bringing the value of this program to $1+ million. Prior to receiving this increase in funding, the program conducted its fifth year of career-relevant instruction via hands-on teacher learning, impacting nearly 30,000 students and 150 teachers. In its first five years, the program has reached 81,413 students and 519 teachers across Georgia. Going forward, in conjunction with the additional funding and gifts from industry, BTTI will be able expand its operations in the urban areas of the state, impacting even more teachers and students.


This programmatic increase will support several initiatives, including hosting an additional cohort of teachers annually in an urban area where the density of industry sits, such as Atlanta or Augusta, and expanding the Equipment Depot and access to lab equipment. Plans for increased access include opening one satellite science equipment loaning office in Northwest Georgia, developing a shipment option with matching private funding, and potential for another satellite location in South Georgia. Further, funds will be allocated toward collaborating with Southwest Georgia RESA to provide teacher training for new science teachers in areas struggling to fill teacher positions, offer training and career path information for guidance counselors on opportunities in the life sciences, explore curriculum enhancement to include medical devices, and network with existing teachers.  

 

“Georgia Bio is the only organization in the State that offers this type of hands-on training program, complemented with classroom supplies and access to career pathway understanding,” said Maria Thacker-Goethe, President and CEO of Georgia Bio. “Investing in improving access to resources for educators can open life changing careers for students and be a boon to Georgia’s economy, and this increase in funding signifies that the State agrees. As the industry continues its rapid growth across the state, our companies need to know there is a workforce pipeline being developed and we help innovatively address that need. I am excited for the future of BTTI and grateful for the support of the State and members of our industry as we endeavor to build upon this program’s value and success.”


“With the explosive growth in biotechnology has come the heightened need for a qualified workforce,” says BTTI Instructor Stan Harrison, also Biotech Pathway Teacher at the Athens Community Career Academy and State Coordinator for the Biotechnician-Assistant Credentialing Exam (BACE). “We hear it echoed again and again that companies are struggling to hire and retain qualified production staff and therefore unable to manufacture high demand and often life-saving products. Quality training starts with highly trained secondary teachers who understand industry recognized standards. Georgia Bio’s BTTI provides a host of professional learning workshops and along with the Equipment Depot, a structured means to network and access cutting edge materials for modern lab training.”


BTTI is a public/private workforce development partnership between the life sciences sector and the State of Georgia. Led by Program Director, Megan Heaphy, BTTI offers hands-on, immersive science teacher professional development for Georgia teachers state-wide. Curriculum is built to highlight and leverage the biotechnology that exists within traditional science courses, including biology and AP biology, chemistry and AP chemistry, physics, environmental biology, agriculture and horticulture, physical science, and life science.


About Georgia Bio 

Georgia Bio (GaBio) is the state’s most impactful life sciences membership organization, advocating for the sector and its diverse innovation pipeline. For over 30 years, GaBio has served its members by supporting companies of all sizes, from early-stage innovators and startups to established industry leaders in biotechnology, pharmaceuticals, and medical technology. GaBio also works closely with universities, academic and research institutions, the investment community, and other critical partners that promote this vibrant sector. GaBio works to shape public policy, improve access to breakthrough technologies, educate lawmakers, provide member programs, strengthens the workforce pipeline, and advance equity within our ecosystem by championing innovative solutions for some of the most pressing challenges of our times. For more information, visit www.gabio.org

 

MEDIA CONTACT: 

Melissa Carter 

404-920-2043 

mcarter@gabio.org 

By Maria Thacker Goethe October 22, 2025
“Evolving FTC and DOJ policies leave investors and innovators navigating a cautious M&A landscape
October 6, 2025
Atlanta, GA — October 6 — Georgia Life Sciences today announced the launch of Vitals, a new podcast series developed in partnership with Cloudcast Media, a leader in branded podcast production. The series will spotlight the people, ideas, and innovations shaping the future of Georgia’s rapidly growing life sciences sector. Hosted by Georgia Life Sciences’ CEO, Maria Thacker Goethe, Vitals will feature in-depth conversations with scientists, entrepreneurs, investors, educators, policymakers, and patient advocates. Each episode will explore the challenges and opportunities facing Georgia’s life sciences ecosystem—spanning biopharma, medical technology, digital health, and advanced manufacturing. “Vitals gives us a powerful platform to showcase the remarkable work happening within our state,” said Maria Thacker Goethe. “By sharing these stories, we’re highlighting not only groundbreaking science but also the collaboration and talent that make Georgia such a vibrant hub for health innovation.” Cloudcast Media, known for its expertise in storytelling and high-quality podcast production, will bring industry insights and technical support to ensure the series reaches audiences across Georgia and beyond. “We’re proud to partner with Georgia Life Sciences on Vitals,” said Charles Parisi, Founder and CEO of Cloudcast. “This series will elevate the voices of innovators who are advancing science, improving patient outcomes, and building Georgia’s reputation as a global life sciences leader. We are very excited that Cloudcast Atlanta can play a role in supporting Maria and the impactful work of Georgia Life Sciences.” The first episode of Vitals launched today and is available on Apple Podcasts, Spotify, and other major streaming platforms, as well as through the Georgia Life Sciences website.
October 1, 2025
September 30, 2025 WASHINGTON, D.C. – John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO) released the following statement on Most Favored Nation policies: "For too many years, Americans have subsidized the research and development necessary to bring newer and better medicines to patients around the world. As we saw with defense spending and NATO, the solution is not to weaken a strategically important American industry, but for other countries to pay their fair share. “Today’s announcement in the Oval Office highlights the problems with a drug delivery system where half of the cost of innovative medicines goes to middlemen and distributors, and where the supply chain distorts prices paid by the American people. We support a new framework that addresses the cost of medicines by simplifying the system - and making medicines directly available to patients. “But importing socialist price controls through most-favored nation policies fundamentally does not address the imbalance in international pricing for innovative medicines. MFN will not lower the out-of-pocket prices that most Americans pay for medicines. Even worse, it will jeopardize the entrepreneurial spirit and deter the capital necessary for a vibrant and essential American biotechnology industry to thrive and may cause most harm to small and midsize biotech companies, which are responsible for discovering more than half of all new treatments. “Without these biotech innovators and a free-market system, we risk slower scientific progress, decreased access to new medicines, compromised national security, fewer American jobs and perhaps most tragically, a diminished hope for those suffering with illness and disease. There are much better ways to address this problem than MFN.” ###
MORE POSTS